Clinical data
Trade names Renormax
AHFS/Drugs.com International Drug Names
  • D
Routes of
ATC code C09AA11 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 50%
Metabolism converted to spiraprilat
Biological half-life 30 to 35 hours
Excretion Hepatic and renal
CAS Number 83647-97-6 YesY
PubChem (CID) 5311447
DrugBank DB01348 N
ChemSpider 4470933 YesY
UNII 96U2K78I3V YesY
KEGG D08529 YesY
Chemical and physical data
Formula C22H30N2O5S2
Molar mass 466.616 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.

Spiraprilat — the active metabolite

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.[1] However, data on its effect upon the renal function are conflicting.[2]


  1. Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). "Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.". Scand J Urol Nephrol. 33 (1): 5762. doi:10.1080/003655999750016294. PMID 10100366.
  2. Noble S, Sorkin E (1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.". Drugs. 49 (5): 75066. doi:10.2165/00003495-199549050-00008. PMID 7601014.

This article is issued from Wikipedia - version of the 9/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.